KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.38
+1.09 (0.44%)
AAPL  259.37
+0.33 (0.13%)
AMD  203.17
-1.51 (-0.74%)
BAC  55.85
-0.33 (-0.59%)
GOOG  329.14
+3.13 (0.96%)
META  653.06
+7.00 (1.08%)
MSFT  479.28
+1.17 (0.24%)
NVDA  184.86
-0.18 (-0.10%)
ORCL  198.52
+9.37 (4.95%)
TSLA  445.01
+9.21 (2.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.